Clinical Evaluation of the Automated COBAS AMPLICOR HCV MONITOR Test Version 2.0 for Quantifying Serum Hepatitis C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2000 Aug 2

PMID 10921954

Citations 7

Authors

M L Yu

W L Chuang

C Y Dai

S C Chen

Z Y Lin

M Y Hsieh

L Y Wang

W Y Chang

Affiliations

Soon will be listed here.

Abstract

A second-generation hepatitis C virus (HCV) quantitative assay (COBAS AMPLICOR HCV MONITOR Test, version 2.0; COBAS HCM-2) has been developed, with the intention of achieving equivalent quantification of all HCV genotypes and improving assay performance. To evaluate the clinical performance of COBAS HCM-2 and its utility in predicting the response to alpha interferon treatment, sera from 215 chronic hepatitis C patients were analyzed and the results were compared with those obtained by the Quantiplex bDNA HCV RNA, version 2.0, assay (bDNA-2). The COBAS HCM-2 had significantly greater sensitivity than bDNA-2 (94.9 versus 88.4%; P < 0.001) when performed with sera from chronic hepatitis C patients who were viremic by a qualitative PCR test. The standard deviations for the within-run and between-run reproducibilities of COBAS HCM-2 were <0. 1 and <0.2, respectively, and it showed an improved linear range between genotypes with the threefold serial dilutions tested (r(2) = 0.986 to 0.995). The COBAS HCM-2 results were positively correlated with the bDNA-2 results, but the values for COBAS HCM-2 were on average 0.96 log lower than the values for bDNA-2. The mean difference in quantification values between these two assays did not differ among samples with different genotypes (0.70 to 1.00 log). No genotype-dependent difference in viral load was observed. The pretreatment viral load was significantly lower in complete responders. By using multivariate analysis, the viral load 2 weeks after the initiation of alpha interferon treatment was the strongest predictor of a complete response. In conclusion, COBAS HCM-2 demonstrated good sensitivity, linearity, and reproducibility and efficiency equal to that of bDNA-2 for the quantification of HCV genotypes 1 and 2. Hence, this assay provides a rapid and reliable method for the quantification of HCV RNA in serum and is useful for the planning of interferon treatment.

Citing Articles

The future of viral hepatitis testing: innovations in testing technologies and approaches.

Peeling R, Boeras D, Marinucci F, Easterbrook P BMC Infect Dis. 2017; 17(Suppl 1):699.

PMID: 29143676 PMC: 5688478. DOI: 10.1186/s12879-017-2775-0.

Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and....

Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G J Clin Microbiol. 2005; 43(6):2590-7.

PMID: 15956369 PMC: 1151897. DOI: 10.1128/JCM.43.6.2590-2597.2005.

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study.

Yu M, Dai C, Chen S, Lee L, Hsieh M, Lin Z BMC Infect Dis. 2005; 5:27.

PMID: 15823212 PMC: 1090579. DOI: 10.1186/1471-2334-5-27.

Quantitative assay of hepatitis C virus RNA using an automated extraction system for specific capture with probes and paramagnetic particle separation.

Miyachi H, Masukawa A, Asai S, Miura T, Tamatsukuri S, Hirose T J Clin Microbiol. 2003; 41(2):572-5.

PMID: 12574248 PMC: 149669. DOI: 10.1128/JCM.41.2.572-575.2003.

External quality assessment program for qualitative and quantitative detection of hepatitis C virus RNA in diagnostic virology.

Schirm J, van Loon A, Valentine-Thon E, Klapper P, Reid J, Cleator G J Clin Microbiol. 2002; 40(8):2973-80.

PMID: 12149361 PMC: 120662. DOI: 10.1128/JCM.40.8.2973-2980.2002.

References

Lunel F, Cresta P, Vitour D, Payan C, Dumont B, Frangeul L . Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology. 1999; 29(2):528-35. DOI: 10.1002/hep.510290237. View

Martell M, Gomez J, Esteban J, Sauleda S, Quer J, Cabot B . High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol. 1999; 37(2):327-32. PMC: 84298. DOI: 10.1128/JCM.37.2.327-332.1999. View

Mellor J, Hawkins A, Simmonds P . Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J Clin Microbiol. 1999; 37(8):2525-32. PMC: 85273. DOI: 10.1128/JCM.37.8.2525-2532.1999. View

Winship P . An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucleic Acids Res. 1989; 17(3):1266. PMC: 331767. DOI: 10.1093/nar/17.3.1266. View

Poynard T, McHutchison J, Goodman Z, Ling M, Albrecht J . Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 1999; 31(1):211-8. DOI: 10.1002/hep.510310131. View

Yu M, Chuang W, Chen S, Lin Z, Hsieh M, Wang L . Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA. J Clin Pathol. 2000; 52(11):807-11. PMC: 501590. DOI: 10.1136/jcp.52.11.807. View

. Acute and chronic hepatitis revisited. Review by an international group. Lancet. 1977; 2(8044):914-9. View

Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-62. DOI: 10.1126/science.2523562. View

Alter M, Margolis H, Krawczynski K, Judson F, Mares A, ALEXANDER W . The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327(27):1899-905. DOI: 10.1056/NEJM199212313272702. View

10.

Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H . Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993; 104(3):877-83. DOI: 10.1016/0016-5085(93)91025-d. View

11.

Lau J, Davis G, Kniffen J, Qian K, Urdea M, Chan C . Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993; 341(8859):1501-4. DOI: 10.1016/0140-6736(93)90635-t. View

12.

Kato N, Yokosuka O, Hosoda K, Ito Y, OHTO M, Omata M . Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993; 18(1):16-20. View

13.

Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H . Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol. 1993; 74 ( Pt 11):2385-90. DOI: 10.1099/0022-1317-74-11-2385. View

14.

Varadaraj K, Skinner D . Denaturants or cosolvents improve the specificity of PCR amplification of a G + C-rich DNA using genetically engineered DNA polymerases. Gene. 1994; 140(1):1-5. DOI: 10.1016/0378-1119(94)90723-4. View

15.

Hayashi J, Kishihara Y, Yoshimura E, Tani Y, Yamaji K, Ikematsu H . Relationship of genotype to level of hepatitis C viraemia determined by competitive polymerase chain reaction. J Infect. 1995; 30(3):235-9. DOI: 10.1016/s0163-4453(95)90785-8. View

16.

Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M . Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995; 22(4 Pt 1):1050-6. View

17.

Smith D, Davidson F, Yap P, Brown H, Kolberg J, Detmer J . Levels of hepatitis C virus in blood donors infected with different viral genotypes. International HCV Collaborative Study Group. J Infect Dis. 1996; 173(3):727-30. DOI: 10.1093/infdis/173.3.727. View

18.

Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M . Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol. 1996; 34(4):901-7. PMC: 228914. DOI: 10.1128/jcm.34.4.901-907.1996. View

19.

Zein N, Rakela J, Krawitt E, Reddy K, Tominaga T, Persing D . Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996; 125(8):634-9. DOI: 10.7326/0003-4819-125-8-199610150-00002. View

20.

Yu M, Chuang W, Chen S, Lu S, Wang J, Lin Z . Treatment of chronic hepatitis C with interferon-alpha: a preliminary report. Kaohsiung J Med Sci. 1996; 12(10):581-9. View